Physician profile
Tamara Budlong Schmidt
NPI 1902879125
$856.53
in general payments reported to CMS, 2019-2025
15 companies · $33.36 in 2025
The $33.36 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $51.90 · 2021: $41.98 · 2022: $34.56 · 2023: $334 · 2025: $33.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $276 · Food and Beverage: $91.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $275.76 |
| Food and Beverage | $91.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $286.12 | 2019-2023 | |
| Intuitive Surgical, INC. | $275.76 | 2023 | Da Vinci Surgical System |
| Sanofi Pasteur INC. | $73.73 | 2019-2023 | |
| Glaxosmithkline, LLC. | $35.44 | 2019 | |
| Novo Nordisk INC | $30.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.84 | 2019 | |
| Cranial Technologies, INC | $17.54 | 2025 | Doc Band |
| Amarin Pharma, INC. | $16.08 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.88 | 2019 | |
| Exact Sciences Corporation | $15.82 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $15.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.01 | 2020 | |
| Merck Sharp & Dohme LLC | $12.66 | 2019 | |
| Allergan, INC. | $12.54 | 2020 | |
| Lilly USA, LLC | $11.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.